171 related articles for article (PubMed ID: 23288588)
1. Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression.
Albrecht K; Droll H; Giesler JM; Nashan D; Meiss F; Reuter K
Psychooncology; 2013 Sep; 22(9):1972-8. PubMed ID: 23288588
[TBL] [Abstract][Full Text] [Related]
2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial).
Ziefle S; Egberts F; Heinze S; Volkenandt M; Schmid-Wendtner M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Heinz A; Hauschild A; Schaefer M
J Immunother; 2011 May; 34(4):403-8. PubMed ID: 21499123
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life, fatigue, and depression under low-dose IFN-α therapy in melanoma patients.
Reuter K; Albrecht K; Seelig H; Meiss F; Mauch C; Kreuzberg N; Nashan D
J Immunother; 2014; 37(9):461-7. PubMed ID: 25304729
[TBL] [Abstract][Full Text] [Related]
5. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
6. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha 2B: a community oncology perspective.
Afzal MZ; Pinnamaneni V; Birendra KC; Davis AT; Koehler TJ; Lakhani N
J Exp Ther Oncol; 2017 Sep; 11(2):91-96. PubMed ID: 28976130
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
10. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J;
Acta Oncol; 2013 Aug; 52(6):1086-93. PubMed ID: 23621752
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon.
Trask PC; Paterson AG; Esper P; Pau J; Redman B
Psychooncology; 2004 Aug; 13(8):526-36. PubMed ID: 15295774
[TBL] [Abstract][Full Text] [Related]
12. Self-efficacy and pain catastrophizing in systemic lupus erythematosus: relationship to pain, stiffness, fatigue, and psychological distress.
Somers TJ; Kurakula PC; Criscione-Schreiber L; Keefe FJ; Clowse ME
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1334-40. PubMed ID: 22505314
[TBL] [Abstract][Full Text] [Related]
13. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.
Rataj D; Jankowiak B; Krajewska-Kułak E; Van Damme-Ostapowicz K; Nowecki ZI; Rutkowski P; Niczyporuk W
Cancer Nurs; 2005; 28(3):172-8. PubMed ID: 15915059
[TBL] [Abstract][Full Text] [Related]
14. Fatigue in survivors of malignant melanoma and its determinants: a register-based cohort study.
Tibubos AN; Ernst M; Brähler E; Fischbeck S; Hinz A; Blettner M; Zeissig SR; Weyer V; Imruck BH; Binder H; Beutel ME
Support Care Cancer; 2019 Aug; 27(8):2809-2818. PubMed ID: 30539313
[TBL] [Abstract][Full Text] [Related]
15. Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
Tesio V; Ribero S; Castelli L; Bassino S; Leombruni P; Caliendo V; Grassi M; Lauro D; Macripò G; Torta RGV
Melanoma Res; 2017 Jun; 27(3):277-280. PubMed ID: 28207426
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
18. [Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
Kreutzer K; Bonnekoh B; Franke I; Ulrich J; Gollnick H
J Dtsch Dermatol Ges; 2004 Aug; 2(8):689-94. PubMed ID: 16279234
[TBL] [Abstract][Full Text] [Related]
19. Fatigue in patients with cancer receiving interferon alpha.
Dean GE; Spears L; Ferrell BR; Quan WD; Groshon S; Mitchell MS
Cancer Pract; 1995; 3(3):164-72. PubMed ID: 7599673
[TBL] [Abstract][Full Text] [Related]
20. Psychological status and coping with illness in patients with malignant melanoma.
Vurnek M; Buljan M; Situm M
Coll Antropol; 2007 Jan; 31 Suppl 1():53-6. PubMed ID: 17469751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
